Loading...
Loading...
TCRX| Name | Value |
|---|---|
| Revenues | 6.8M |
| Cost of Revenue | 1.5M |
| Gross Profit | 5.3M |
| Operating Expense | 29.5M |
| Operating I/L | -22.7M |
| Other Income/Expense | 0.2M |
| Interest Income | 1.1M |
| Pretax | -22.6M |
| Income Tax Expense | 1.1M |
| Net Income/Loss | -22.6M |
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company specializing in developing T cell receptor-engineered T cell therapies for cancer treatment. Its product pipeline includes TSC-100 and TSC-101 for hematologic malignancies, aiming to eliminate residual leukemia and prevent relapse post stem cell transplantation, as well as TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for solid tumor treatment. Additionally, the company is working on vaccines for infectious diseases, including SARS-CoV-2. TScan Therapeutics, Inc. also collaborates with Novartis Institutes for BioMedical Research, Inc. to identify novel cancer antigens. Its revenue model is based on the development and commercialization of these innovative therapies and vaccines.
